Endocyte is a biopharmaceutical company engaged in the development of targeted therapies to treat cancer and inflammatory diseases. The company utilizes its proprietary technology in creating novel SMDCs and companion imaging diagnostics for personalized targeted therapies. Endocyte’s SMDCs actively target receptors that are overexpressed on diseased cells relative to healthy cells – facilitating patient treatment with highly active drugs at greater doses, delivered more frequently and over longer periods than with the untargeted drug alone. For more information, visit the company’s Web site: http://www.endocyte.com
Let us hear your thoughts below: